This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices. Efforts to reduce the net ...

With health care costs rising and obesity-related conditions impacting workplace productivity, employers are increasingly ...

One recent morning, curiosity led me to a video promoting Mr. Kennedy’s Make America Healthy Again movement. With the ...

An early-life responsive parenting intervention resulted in lower body mass index from age 3 to 9 compared with a control intervention. This group difference was driven by effects on female ...

Sociologist Jessica Calarco explains why the right keeps winning, and how progressive narratives can turn the tide ...

Kidney cancer incidences are rising among people under 50, linked to factors like obesity, hypertension, and smoking. This ...

Reflecting on World Obesity Day‘’ From misallocated health funds to the normalization of 'family diabetes,' South ...

On March 5, they unanimously approved rezoning rural AG2 acreage — previously limited to one home per acre — into a ...

Tirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Anti-obesity drugs are only part of the larger treatment plan for most patients. Exercise and nutrition are also keys.

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...